hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06310954, orgStudyIdInfo id: 2022-KY-012, briefTitle: Ketogenic Diet in Pediatric Intractable Epilepsy, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-08-11, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-04-30, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, class: OTHER, descriptionModule briefSummary: This study aims to evaluate the efficacy of a ketogenic diet in treating pediatric intractable epilepsy and to explore its relationship with changes in inflammatory markers. The investigators plan to recruit 59 participants with intractable epilepsy, 39 of whom will receive a combination of ketogenic diet and conventional antiepileptic drugs, while 20 will receive only conventional drugs. The study will assess the impact of the ketogenic diet on epilepsy control and inflammatory markers, hoping to discover new treatment strategies., conditionsModule conditions: Epilepsy in Children, conditions: Epilepsy Intractable, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 59, type: ESTIMATED, armsInterventionsModule interventions name: Early ketogenic diet combined with conventional pharmacotherapy., interventions name: Common diet combined with conventional pharmacotherapy, outcomesModule primaryOutcomes measure: Epilepsy Control Response Rate, secondaryOutcomes measure: Inflammatory Marker Levels, eligibilityModule sex: ALL, minimumAge: 6 Months, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Sun Yat Sen Memorial Hospital， Sun Yat Sen University, status: RECRUITING, city: Guangzhou, state: Guangdong, zip: 510000, country: China, contacts name: Dongfang Li, role: CONTACT, phone: +8615521284993, email: ldf201310@163.com, contacts name: Dongfang Li, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06310941, orgStudyIdInfo id: ABSENTA, secondaryIdInfos id: Pending, type: OTHER, domain: Ceim HCSC (ERB of Hospital Clinico San Carlos)), briefTitle: Mechanical Insufflation-exsufflation and Hypertonic Saline in Nosocomial Bacterial Respiratory Tract Infection, acronym: ABSENTA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-12-01, primaryCompletionDateStruct date: 2026-10-30, completionDateStruct date: 2026-12-30, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Hospital San Carlos, Madrid, class: OTHER, descriptionModule briefSummary: Randomized open label clinical trial to evaluate IEM and HS as concomitant therapy for respiratory tract infection in patients under artificial ventilation in the ICU.Lung infection is a serious complication that may occur during hospital stay and may need artificial respiration or even develop during artificial ventilation for other causes.Current specific treatment consists of intravenous antibiotics. The current study evaluated whether aspiration and drainage of infected sputum helps curing this severe complication and whether nebulized HS has additional benefits, like eradicating bacteria or reducing inflammation., conditionsModule conditions: Nosocomial Infection, conditions: Nosocomial Pneumonia, conditions: Tracheobronchitis, conditions: Mechanical Ventilation Complication, conditions: Endotracheal Intubation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: randomized, open label, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Mechanical insufflation-exsufflation, interventions name: Standard of Care, interventions name: Hypertonic saline with hyaluronic acid, outcomesModule primaryOutcomes measure: Median SOFA score increase >2 points on day 4, primaryOutcomes measure: Median respiratory support-free days increase at day 28, primaryOutcomes measure: Percentage of subjects surviving/dying day 28, secondaryOutcomes measure: Subjects with bacterial eradication in respiratory samples at day 4 after randomization, secondaryOutcomes measure: Subjects with bacterial eradication in respiratory samples at end of systemic antibiotic therapy, secondaryOutcomes measure: Median Length of ICU stay, secondaryOutcomes measure: Median antibiotic-free days at 28 days, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06310915, orgStudyIdInfo id: CROC202310, briefTitle: Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-17, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Guangzhou Institute of Respiratory Disease, class: OTHER, descriptionModule briefSummary: Oral chemotherapeutic drugs were analyzed in patients with driver gene negative locally advanced/advanced non-small cell lung cancer with PS score 2 A prospective, single-arm, multicenter, observational study on the efficacy and safety of radiochemotherapy combined with PD-1 inhibitor., conditionsModule conditions: Non-small Cell Lung Cancer Stage IIIB/IV, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Navelbine oral,Pembrolizumab, outcomesModule primaryOutcomes measure: Progression-free survival time, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Guangzhou Medical University, status: RECRUITING, city: Guangdong, state: Guangzhou, zip: 510000, country: China, contacts name: zhou chegnzhi, doctor, role: CONTACT, phone: 13560351186, email: doctorzcz@163.com, hasResults: False
protocolSection identificationModule nctId: NCT06310902, orgStudyIdInfo id: 2024KY022, briefTitle: Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-03-01, completionDateStruct date: 2026-09-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Fujian Medical University Union Hospital, class: OTHER, descriptionModule briefSummary: Preoperative neoadjuvant chemotherapy is widely used in treating patients with borderline resectable pancreatic cancer (BRPC). However, there are limitations in this field. Treatment strategies and definitions for BRPC patients differ, and the efficacy and prognosis of neoadjuvant chemotherapy vary greatly.This study aims to utilize single-cell sequencing technology to investigate in-depth the composition and interactions of the tumor microenvironment in patients from the surgical-only group and the preoperative neoadjuvant chemotherapy group., conditionsModule conditions: Pancreatic Neoplasms, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Single-cell Sequencing Analysis, outcomesModule primaryOutcomes measure: Bioinformatics analysis of single-cell sequencing results, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fujian Medical University Union Hospital, status: RECRUITING, city: Fuzhou, state: Fujian, zip: 350001, country: China, contacts name: Yu Pan, M.D, role: CONTACT, phone: +86 18900316399, email: yupan199002@163.com, geoPoint lat: 26.06139, lon: 119.30611, hasResults: False
protocolSection identificationModule nctId: NCT06310889, orgStudyIdInfo id: EPIC-Baseline-Survey, briefTitle: Evaluation of Palliative Care Co-treatment by Attending Physicians and Nurses: an Online Survey as Part of the Project, acronym: EPIC-BS, statusModule overallStatus: WITHDRAWN, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Charite University, Berlin, Germany, class: OTHER, collaborators name: European Commission, collaborators name: National and Kapodistrian University of Athens, collaborators name: King's College Hospital NHS Trust, descriptionModule briefSummary: The subject of the study is an online survey of doctors and nurses who provide (intensive) medical care to patients., conditionsModule conditions: Palliative Medicine, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 0, type: ACTUAL, outcomesModule primaryOutcomes measure: Barriers 1, primaryOutcomes measure: Barriers 2, secondaryOutcomes measure: Measures 1, secondaryOutcomes measure: Measures 2, secondaryOutcomes measure: Resources 1, secondaryOutcomes measure: Resources 2, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 67 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06310876, orgStudyIdInfo id: M24-852, briefTitle: A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-14, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Calico Life Sciences LLC, class: INDUSTRY, collaborators name: AbbVie, descriptionModule briefSummary: This is a randomized, blinded, placebo and active-controlled, 4-period, crossover design thorough QT/QTc (TQT) study to evaluate the effect of ABBV-CLS-7262 on cardiac repolarization in healthy adult subjects., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 72, type: ESTIMATED, armsInterventionsModule interventions name: ABBV-CLS-7262, interventions name: ABBV-CLS-7262, interventions name: Placebo, interventions name: Moxifloxacin 400mg, outcomesModule primaryOutcomes measure: To evaluate the effect of ABBV-CLS-7262 on the QTc interval in healthy adult subjects, secondaryOutcomes measure: To evaluate the effects of ABBV-CLS-7262 on change in electrocardiogram (ECG) parameters, secondaryOutcomes measure: To evaluate the sensitivity of QTc measurement using moxifloxacin, secondaryOutcomes measure: To evaluate the effect of ABBV-CLS-7262 on T-wave morphology, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: AbbVie Clinical Pharmacology Research Unit (ACPRU), status: RECRUITING, city: Grayslake, state: Illinois, zip: 60030, country: United States, geoPoint lat: 42.34447, lon: -88.04175, hasResults: False
protocolSection identificationModule nctId: NCT06310863, orgStudyIdInfo id: EXOCOBIO-NASAL-01, briefTitle: Pivotal Study to Evaluate the Efficacy and Safety of Injection With LASBEAU Strong in Correction of Nasolabial Folds, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-10-07, primaryCompletionDateStruct date: 2020-11-24, completionDateStruct date: 2020-11-24, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Asan Medical Center, class: OTHER, descriptionModule briefSummary: Background: Nonsurgical injectable treatments have become popular for aesthetic purposes. In recent years, cross-linked hyaluronic acid (HA) fillers containing lidocaine have been used to correct the nasolabial folds.Aim: The aim of this study was to demonstrate the efficacy and safety of a new HA filler (LASBEAU Strong) (24 mg/mL) compared with a conventional HA filler (Restylane Lyft) for the restoration of nasolabial folds.Patients/methods: A total of 72 subjects were enrolled and randomized to receive injections of the new HA filler (test group) or the conventional HA filler (control group) on the left or right side of the face. The mean value difference in the Wrinkle Severity Rating Scale (WSRS) scores at week 24 evaluated primary efficacy. The WSRS and the Global Aesthetic Improvement Scale (GAIS) at weeks 8, 16, 24, and 48 evaluated secondary efficacy. Adverse events, laboratory tests, and a check of vital signs at every visit assessed safety., conditionsModule conditions: Dermal Fillers, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized, Matched pairs, Active controlled, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 72, type: ACTUAL, armsInterventionsModule interventions name: LASBEAU Strong or Restylane Lyft injection as hyaluronic acid fillers, outcomesModule primaryOutcomes measure: Differences in the mean value of the Wrinkle Severity Rating Scale (WSRS) between the test group and the control group, secondaryOutcomes measure: The mean value differences in the WSRS scores between the test group and the control group, secondaryOutcomes measure: Differences in GAIS mean values between test and control groups, secondaryOutcomes measure: Percentage of subjects with WSRS score improvement of at least 1 point, eligibilityModule sex: ALL, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Asan mediccal center, city: Seoul, state: Songpa-gu, zip: 05505, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06310850, orgStudyIdInfo id: KEAH-238, briefTitle: The Effect of Preprocedural Subanesthetic Ketamine on Pain and Anxiety, statusModule overallStatus: COMPLETED, startDateStruct date: 2013-06-01, primaryCompletionDateStruct date: 2023-01-01, completionDateStruct date: 2023-06-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Ankara Ataturk Sanatorium Training and Research Hospital, class: OTHER_GOV, descriptionModule briefSummary: The thoracic epidural catheterization (TEC) can be both uncomfortable and fearful for patients when done awake with the thought that the procedure may be painful. The aim of this study was to assess the effect of subanesthetic intravenous ketamine administration on pain and anxiety during the TEC procedure., conditionsModule conditions: Epidural Catheterization, conditions: Thoracic, conditions: Procedural Pain, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This study was designed as a randomized, prospective study, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: Ketamine, interventions name: Placebo, outcomesModule primaryOutcomes measure: Visual analog scale (VAS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ankara Atatürk Sanatorium Training and Research Hospital, city: Ankara, state: Keçiören, zip: 06290, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06310824, orgStudyIdInfo id: MAB-22-101, briefTitle: Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-07, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Xentria, Inc., class: INDUSTRY, descriptionModule briefSummary: A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®, conditionsModule conditions: Healthy Participants, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 225, type: ESTIMATED, armsInterventionsModule interventions name: MAB-22, interventions name: EU-Prolia®, interventions name: US-Prolia®, outcomesModule primaryOutcomes measure: Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-∞), primaryOutcomes measure: Maximum observed serum concentration (Cmax), secondaryOutcomes measure: Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC0-last), secondaryOutcomes measure: Area under the concentration-time curve, secondaryOutcomes measure: Area under the concentration-time curve, eligibilityModule sex: MALE, minimumAge: 25 Years, maximumAge: 55 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06310785, orgStudyIdInfo id: TJ-IRB20231191, briefTitle: Esketamine Anesthesia in Thoracic Surgery, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2024-08-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Hui Xu, class: OTHER, descriptionModule briefSummary: Esketamine group was induced with esketamine 0.5 mg/kg, propofol 2 mg/kg, and rocuronium bromide 0.9 mg/kg. Anesthesia is maintained with propofol 5 mg/kg/h and esketamine 0.5 mg/kg/h. Anesthesia induction in the opioid group Sufentanil 0.5 ug/kg, propofol 2 mg/kg, rocuronium bromide 0.9 mg/kg. Anesthesia is maintained with propofol 5 mg/kg/h and remifentanil 1 ug/kg/h., conditionsModule conditions: General Anesthesia, conditions: Thoracic Surgery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, maskingDescription: Neither the patients who participated in the trial nor the analysis of the results of the study were aware of the experimental group, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 84, type: ESTIMATED, armsInterventionsModule interventions name: Esketamine, interventions name: Sufentanil, outcomesModule primaryOutcomes measure: Dynamic compliance of the ventilator-side lung during 30 minutes of one-lung ventilation during operation, secondaryOutcomes measure: Lung compliance during double lung ventilation during operation, secondaryOutcomes measure: Compliance of the ventilator-side lung during one-lung ventilation during operation, secondaryOutcomes measure: Blood pressure, secondaryOutcomes measure: Heart rate, secondaryOutcomes measure: Blood gas analysis results, secondaryOutcomes measure: Serum inflammatory factor levels, secondaryOutcomes measure: cognitive function, secondaryOutcomes measure: Postoperative nausea and vomiting, secondaryOutcomes measure: Depression and anxiety, secondaryOutcomes measure: Postoperative pain, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06310772, orgStudyIdInfo id: NSF 2304297, briefTitle: Assessing Comorbidities in Epilepsy Using Eye Movement Recordings, acronym: ACER, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Eysz, Inc., class: INDUSTRY, collaborators name: Wake Forest University Health Sciences, collaborators name: Children's Hospital of Orange County, collaborators name: University of Colorado, Denver, descriptionModule briefSummary: This study wants to make it easier to find kids with a type of epilepsy called childhood absence epilepsy (CAE) who might have problems with ongoing seizures and thinking. Right now, doctors use tests that can be expensive and take a long time. Eysz is developing a system that looks at how kids move their eyes which might help find CAE more quickly and accurately. This study will compare Eysz with the usual tests to see if it can predict seizures and thinking problems in kids with CAE. The goal is to find these problems earlier and help kids do better in school and life., conditionsModule conditions: Childhood Absence Epilepsy, conditions: Absence Seizures, conditions: Epilepsy Comorbidities, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Eye Movements to Diagnose CAE, secondaryOutcomes measure: Eye Movements to Diagnose Attention challenges, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Children's Hospital Orange County, city: Orange, state: California, zip: 92868, country: United States, geoPoint lat: 33.78779, lon: -117.85311, locations facility: Wake Forest Baptist Health, city: Winston-Salem, state: North Carolina, zip: 27157, country: United States, geoPoint lat: 36.09986, lon: -80.24422, hasResults: False